Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ProPhase Labs (PRPH) EBITDA: 2009-2024

Historic EBITDA for ProPhase Labs (PRPH) over the last 16 years, with Dec 2024 value amounting to -$53.3 million.

  • ProPhase Labs' EBITDA fell 3.87% to -$6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.7 million, marking a year-over-year decrease of 57.32%. This contributed to the annual value of -$53.3 million for FY2024, which is 198.57% down from last year.
  • Latest data reveals that ProPhase Labs reported EBITDA of -$53.3 million as of FY2024, which was down 198.57% from -$17.8 million recorded in FY2023.
  • In the past 5 years, ProPhase Labs' EBITDA ranged from a high of $19.4 million in FY2022 and a low of -$53.3 million during FY2024.
  • Moreover, its 3-year median value for EBITDA was -$17.8 million (2023), whereas its average is -$17.2 million.
  • Its EBITDA has fluctuated over the past 5 years, first spiked by 386.27% in 2021, then plummeted by 198.57% in 2024.
  • ProPhase Labs' EBITDA (Yearly) stood at -$2.1 million in 2020, then skyrocketed by 386.27% to $6.1 million in 2021, then skyrocketed by 217.48% to $19.4 million in 2022, then slumped by 191.98% to -$17.8 million in 2023, then slumped by 198.57% to -$53.3 million in 2024.